Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02TNR
|
||||
| Former ID |
DNC006136
|
||||
| Drug Name |
N-(1-((cyanomethyl)carbamoyl)cyclohexyl)benzamide
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H19N3O2
|
||||
| Canonical SMILES |
C1CCC(CC1)(C(=O)NCC#N)NC(=O)C2=CC=CC=C2
|
||||
| InChI |
1S/C16H19N3O2/c17-11-12-18-15(21)16(9-5-2-6-10-16)19-14(20)13-7-3-1-4-8-13/h1,3-4,7-8H,2,5-6,9-10,12H2,(H,18,21)(H,19,20)
|
||||
| InChIKey |
CSOZFSBRJJRGIA-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cathepsin K | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Lysosome | ||||
| Osteoclast differentiation | |||||
| Toll-like receptor signaling pathway | |||||
| Rheumatoid arthritis | |||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | ||||
| RANKL Signaling Pathway | |||||
| IL2 Signaling Pathway | |||||
| Reactome | Collagen degradation | ||||
| Degradation of the extracellular matrix | |||||
| Activation of Matrix Metalloproteinases | |||||
| Trafficking and processing of endosomal TLR | |||||
| MHC class II antigen presentation | |||||
| WikiPathways | RANKL/RANK Signaling Pathway | ||||
| Osteoclast Signaling | |||||
| References | |||||
| REF 1 | J Med Chem. 2006 Feb 9;49(3):1066-79.Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.